Kidney Stones, Liver Protection, and Antiurolithic Properties

Evidence Review

12-week clinical trial — metabolic parameters in stone-forming patients. Pucci et al. (2018) enrolled 56 patients with confirmed kidney stones at a Brazilian urology center, administering P. niruri as an aqueous infusion tea for 12 weeks [1]. The primary endpoints were changes in 24-hour urine chemistry — the standard clinical tool for understanding stone-forming risk. The results were striking among the subgroups with specific metabolic abnormalities driving their stones: hyperoxaluric patients saw urinary oxalate fall from 59.0±11.7 to 28.8±16.0 mg/24h (p<0.001), a 51% reduction. Hyperuricosuria patients showed significant reductions in uric acid. All patients showed increased urinary magnesium and potassium. Stone count per patient declined from 3.2 to 2.0 (p<0.001). No significant adverse effects on serum metabolic parameters were recorded. The study was uncontrolled — there was no placebo arm — which limits the ability to distinguish P. niruri's effect from regression to the mean. However, the magnitude of the oxalate reduction and its biological coherence with known mechanisms of the plant give the findings considerable weight [1].

Randomized placebo-controlled trial — urinary calcium normalization. Nishiura et al. (2004) conducted one of the better-controlled kidney stone studies, enrolling 69 calcium stone-forming (CSF) patients and randomizing them to P. niruri or placebo for 90 days [2]. Among the subset of patients with hypercalciuria — the most clinically important metabolic risk factor for calcium stones — P. niruri induced a significant reduction in urinary calcium from 4.8±1.0 to 3.4±1.1 mg/kg/24h (p<0.05), while no change was seen in the placebo group. Effects across the broader population without hypercalciuria were minimal, suggesting that chanca piedra is most beneficial in the metabolically abnormal patient rather than as a universal stone preventive [2]. The study size (n=69) was moderate, and the 90-day duration captures meaningful metabolic change. This is the best evidence for a specific, targeted effect in a well-characterized patient subgroup.

Randomized trial — enhancement of lithotripsy outcomes. Micali et al. (2006) conducted a randomized prospective study in 150 patients undergoing extracorporeal shock wave lithotripsy (ESWL) for renal stones, assigning 78 to P. niruri supplementation for three months and 72 to observation only [3]. The primary endpoint was stone-free status at follow-up imaging. The overall stone-free rate was 93.5% in the treatment group versus 83.3% in controls. For the most difficult location — lower caliceal stones, which resist gravitational clearance — stone-free rates were 93.7% versus 70.8% (a clinically meaningful 23-percentage-point difference). No adverse effects were reported in either group. This was not blinded, which introduces potential bias, but the objective radiographic endpoint (stone-free on imaging) is difficult to confound with expectation effects. The post-ESWL setting is a practical, well-defined clinical niche where chanca piedra's antiurolithic properties may have the greatest impact [3].

Systematic review and meta-analysis. Dhawan and Olweny (2020) synthesized the available controlled studies on P. niruri for kidney stones, concluding that there is "limited clinical evidence" for modest but meaningful effects on stone size reduction and clearance [4]. The meta-analysis was limited by small numbers of adequately controlled trials and heterogeneous study designs. The authors also analyzed Google Trends data, finding that public interest in chanca piedra has grown substantially since 2015 and now rivals search interest in conventional interventions like ESWL — a finding that underscores the gap between patient demand and available evidence. The review did not find evidence of harm [4].

Double-blind RCT — liver function in alcoholic hepatitis. Sowjanya et al. (2021) conducted a block-randomized, double-blind, placebo-controlled trial in 100 patients with mild-to-moderate alcoholic hepatitis, with 71 completing four weeks of treatment [5]. The primary liver function endpoints (ALT, AST, bilirubin) did not improve significantly with P. niruri compared to placebo — an important null finding that tempers enthusiasm for its hepatoprotective effects in established liver disease. However, total antioxidant capacity increased significantly in the P. niruri group (p=0.034), and appetite improved significantly (p=0.03). The antioxidant finding aligns with preclinical data on the plant's induction of hepatic superoxide dismutase and catalase. The null finding on liver enzymes over four weeks may reflect the study's short duration — hepatoprotective effects in the context of ongoing alcohol use may require longer intervention or cessation of alcohol [5].

Pharmacological review. Lee et al. (2016) systematically reviewed 35 years of scientific literature on P. niruri, cataloguing its hepatoprotective, antiviral, antibacterial, hypolipidaemic, hypoglycaemic, analgesic, anti-inflammatory, cardioprotective, antiurolithic, and antihyperuricaemic properties [6]. The review identifies hepatoprotection and antiviral activity against hepatitis B as the areas with the strongest mechanistic evidence, while acknowledging that clinical trial data remains limited and often of modest quality. The authors recommend additional toxicological and pharmacokinetic studies as prerequisites for formal drug development. The breadth of documented pharmacological activity reflects the richness of P. niruri's phytochemical profile, though it also highlights that many effects have been characterized in vitro or in animal models rather than in humans [6].

Evidence strength summary. For kidney stone prevention and post-lithotripsy clearance, the evidence is moderately strong — multiple controlled clinical trials show consistent biological effects on urinary stone-forming parameters, with one randomized trial showing a clinically meaningful improvement in lithotripsy outcomes. For liver protection, the mechanistic rationale is compelling but the human clinical data is limited and mixed. Chanca piedra is one of the better-supported herbal options for kidney stone management, with a favorable safety profile and centuries of traditional use backing it. The limitations are the relatively small size of most trials and the need for larger, blinded, multi-center studies to confirm efficacy across stone types and patient populations.